• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.

作者信息

Rifkin Robert M, Abonour Rafat, Shah Jatin J, Mehta Jayesh, Narang Mohit, Terebelo Howard, Gasparetto Cristina, Toomey Kathleen, Hardin James W, Lu Jane Jie, Kenvin Laurie, Srinivasan Shankar, Knight Robert, Nagarwala Yasir, Durie Brian G M

机构信息

a US Oncology Research, Inc. , The Woodlands , TX , USA ;

b Indiana University Cancer Center , Indianapolis , IN , USA ;

出版信息

Leuk Lymphoma. 2016 Sep;57(9):2228-31. doi: 10.3109/10428194.2015.1132419. Epub 2016 Jan 13.

DOI:10.3109/10428194.2015.1132419
PMID:26766599
Abstract
摘要

相似文献

1
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.Connect MM® - 多发性骨髓瘤疾病登记处：接受来那度胺治疗患者的第二原发性恶性肿瘤发病率
Leuk Lymphoma. 2016 Sep;57(9):2228-31. doi: 10.3109/10428194.2015.1132419. Epub 2016 Jan 13.
2
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.来那度胺治疗初诊多发性骨髓瘤的第二原发恶性肿瘤：一项个体患者数据的荟萃分析。
Lancet Oncol. 2014 Mar;15(3):333-42. doi: 10.1016/S1470-2045(13)70609-0. Epub 2014 Feb 11.
3
Multiple myeloma and other malignancies: a pilot study from the Houston VA.多发性骨髓瘤及其他恶性肿瘤：来自休斯顿退伍军人事务部的一项初步研究。
Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):102-6. doi: 10.1016/j.clml.2013.10.006. Epub 2013 Nov 15.
4
Lenalidomide: second cancers.来那度胺：二次癌症
Prescrire Int. 2012 May;21(127):130.
5
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.来那度胺治疗背景下的第二原发性恶性肿瘤：对纳入骨髓瘤XI试验的2732例骨髓瘤患者的分析。
Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114.
6
A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan.一项在台湾地区开展的来那度胺治疗多发性骨髓瘤患者的非干预性观察性注册登记研究。
J Formos Med Assoc. 2017 Sep;116(9):705-710. doi: 10.1016/j.jfma.2016.11.005. Epub 2016 Dec 21.
7
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.来那度胺治疗复发/难治性多发性骨髓瘤患者的第二原发性恶性肿瘤回顾。
Blood. 2012 Mar 22;119(12):2764-7. doi: 10.1182/blood-2011-08-373514. Epub 2012 Feb 9.
8
Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.在新型治疗时代多发性骨髓瘤的二次原发性恶性肿瘤风险是否增加？ 台湾基于人群的回顾性队列研究。
Sci Rep. 2020 Sep 1;10(1):14393. doi: 10.1038/s41598-020-71243-z.
9
Lenalidomide and second malignancies in myeloma patients.来那度胺与骨髓瘤患者的第二原发性恶性肿瘤
Lancet Oncol. 2014 Mar;15(3):253-4. doi: 10.1016/S1470-2045(14)70001-4. Epub 2014 Feb 11.
10
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.来那度胺维持治疗多发性骨髓瘤患者干细胞移植后。
N Engl J Med. 2012 May 10;366(19):1782-91. doi: 10.1056/NEJMoa1114138.

引用本文的文献

1
Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients.多发性骨髓瘤干细胞移植后十年发生第二原发性恶性肿瘤及死亡的风险增加：对14532例患者的分析
Cureus. 2021 Jul 13;13(7):e16372. doi: 10.7759/cureus.16372. eCollection 2021 Jul.
2
Future Directions in Maintenance Therapy in Multiple Myeloma.多发性骨髓瘤维持治疗的未来方向
J Clin Med. 2021 May 24;10(11):2261. doi: 10.3390/jcm10112261.
3
Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma.
多发性骨髓瘤患者累积接受马法兰化疗与随后发生急性髓性白血病和骨髓增生异常综合征的风险。
Eur J Haematol. 2021 Aug;107(2):275-282. doi: 10.1111/ejh.13650. Epub 2021 May 28.
4
Second primary malignancies in multiple myeloma: A review.多发性骨髓瘤中的第二原发性恶性肿瘤：综述。
Blood Rev. 2021 Mar;46:100757. doi: 10.1016/j.blre.2020.100757. Epub 2020 Sep 6.
5
Connect MM Registry as a national reference for United States multiple myeloma patients.将 MM 注册中心作为美国多发性骨髓瘤患者的国家参考。
Cancer Med. 2020 Jan;9(1):35-42. doi: 10.1002/cam4.2656. Epub 2019 Nov 7.
6
Is lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma?来那度胺是否是多发性骨髓瘤自体移植后的标准治疗方法？
Leukemia. 2019 Mar;33(3):588-596. doi: 10.1038/s41375-019-0383-2. Epub 2019 Jan 28.
7
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.移植后维持治疗对多发性骨髓瘤患者健康相关生活质量的影响：来自 Connect® MM 注册研究的数据。
Ann Hematol. 2018 Dec;97(12):2425-2436. doi: 10.1007/s00277-018-3446-y. Epub 2018 Jul 29.
8
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.Connect MM 中初诊多发性骨髓瘤患者 ASCT 后维持治疗对结局的影响。
Blood Adv. 2018 Jul 10;2(13):1608-1615. doi: 10.1182/bloodadvances.2018017186.
9
The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.既往恶性肿瘤对多发性骨髓瘤患者二次恶性肿瘤及生存的影响：一项基于人群的研究。
Blood Adv. 2017 Nov 22;1(25):2392-2398. doi: 10.1182/bloodadvances.2017007930. eCollection 2017 Nov 28.
10
[Outcomes of lenalidomide-based treatment for 57 patients of relapsed or refractory multiple myeloma].[57例复发或难治性多发性骨髓瘤患者基于来那度胺治疗的结果]
Zhonghua Xue Ye Xue Za Zhi. 2017 Jun 14;38(6):487-493. doi: 10.3760/cma.j.issn.0253-2727.2017.06.005.